A Phase 2 interventional study of pemetrexed and carboplatin in Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Terminated at 12 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing carboplatin in Small Cell Lung Carcinoma — 6 open to participants now, 9 under way, 1 of them phase 3. Carboplatin · Small Cell Lung Carcinoma.
Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, this one is the 33rd largest by enrollment, is one of 2 that started in 2007, is one of 22 in phase 2, and was the 9th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →6 of the 36 studies testing carboplatin in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
Sehhoon Park · Sites in Korea, Republic of
Ages 19+
Anhui Provincial Cancer Hospital · Sites in China
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 26 · Phase 3 4
First in 1998; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 48 across the 36 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company: none open now, 1 under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company, this one is the 12th largest by enrollment, is one of 3 that started in 2007, is one of 5 in phase 2, and was the 6th registered.
Eli Lilly and Company’s Small Cell Lung Carcinoma studies by the year they started, since 1998.
4 of the studies testing carboplatin in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05856695Intergroupe Francophone de Cancerologie ThoraciqueDurvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) | 2026-11 |
| NCT06838208Anhui Provincial Cancer HospitalTislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | 2027-03-01 |
| NCT06830694Sehhoon ParkClinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | 2027-03-31 |
| NCT06449209BioNTech SESafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 12 in Small Cell Lung Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, phase II, open-label trial to evaluate the efficacy of pemetrexed + carboplatin combined with thoracic radiotherapy in patients with Limited Stage of small cell lung cancer
Two 21-day cycles of pemetrexed (500 milligrams per square meter [mg/m2] intravenous [IV] infusion) and carboplatin (target area under the curve [AUC] 5 IV infusion) followed by two 21-day cycles of pemetrexed (500 mg/m2 IV infusion) and carboplatin (target AUC 5 IV infusion) with concurrent radiotherapy (2 Gray [Gy] per fraction, 5 fractions per week, up to a dose of 50 Gy is administered).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed · Drug: carboplatin · Procedure: radiotherapy
500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
Also known as: LY231514, Alimta
Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
Proportion of Patients With a Complete or Partial Response (Overall Response Rate [ORR])
Overall Response Rate (ORR) was defined as the proportion of participants having either a Complete or Partial response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions.
Time frame: baseline to measured response after chemotherapy and radiation
Progression-free Survival
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.
Time frame: baseline to measured progressive disease
Overall Survival
Overall survival is the duration from enrollment to death (includes 1 year follow-up). For patients who are alive, overall survival is censored at the last contact.
Time frame: baseline to date of death from any cause, 1 year
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: time of response to progressive disease
Pharmacology Toxicity
Radiation Therapy Oncology Group (RTOG) criteria were used for assessing toxicity. Toxicity grade reflected the most severe degree occurring during the evaluated period, not an average. When two criteria were available for similar toxicities, the one resulting in the more severe grade was used. Toxiccity grades range from 0 to 5. Toxicity grade = 5 if that toxicity caused the death of the patient.
Time frame: every 21-day cycle for 4 cycles
| Milestone | Pemetrexed + Carboplatin |
|---|---|
| Started | 4 |
| Completed | 0 |
| Not completed | 4 |
| Withdrew: Sponsor decision | 4 |
Overall Response Rate (ORR) was defined as the proportion of participants having either a Complete or Partial response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions.
No measurements were reported for this outcome.
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.
No measurements were reported for this outcome.
Overall survival is the duration from enrollment to death (includes 1 year follow-up). For patients who are alive, overall survival is censored at the last contact.
No measurements were reported for this outcome.
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
No measurements were reported for this outcome.
Radiation Therapy Oncology Group (RTOG) criteria were used for assessing toxicity. Toxicity grade reflected the most severe degree occurring during the evaluated period, not an average. When two criteria were available for similar toxicities, the one resulting in the more severe grade was used. Toxiccity grades range from 0 to 5. Toxicity grade = 5 if that toxicity caused the death of the patient.
| participants | Pemetrexed + Carboplatin |
|---|---|
| Cycle 3: Grade 2 Hematologic White Blood Cell | 1 |
| Cycle 3: Grade 1 Platelets | 1 |
| Cycle 3: Grade 3 Neutrophils | 1 |
| Cycle 3: Grade 2 Hemoglobin | 1 |
| Cycle 3: Grade 2 Hematocrit | 1 |
| Cycle 4: Grade 3 Hematologic White Blood Cell | 1 |
| Cycle 4: Grade 3 Platelets | 1 |
| Cycle 4: Grade 2 Neutrophils | 1 |
| Cycle 4: Grade 3 Hemoglobin | 1 |
| Cycle 4: Grade 3 Hematocrit | 1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Carboplatin | — | 0/4 (0%) | 2/4 (50%) |
| Event | Pemetrexed + Carboplatin |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/4 |
| Platelet count decreasedInvestigations | 2/4 |
| AnaemiaBlood and lymphatic system disorders | 1/4 |
| NauseaGastrointestinal disorders | 1/4 |
| VomitingGastrointestinal disorders | 1/4 |
| FatigueGeneral disorders | 1/4 |
| Mucosal inflammationGeneral disorders | 1/4 |
| Respiratory tract infectionInfections and infestations | 1/4 |
| AnorexiaMetabolism and nutrition disorders | 1/4 |
| Age Continuous(years) | Pemetrexed + Carboplatin |
|---|---|
| Mean | 59.85 ± 9.45 |
| Sex: Female, Male(Participants) | Pemetrexed + Carboplatin |
|---|---|
| Female | 0 |
| Male | 4 |
| Region of Enrollment(participants) | Pemetrexed + Carboplatin |
|---|---|
| Poland | 2 |
| Spain | 2 |
| Eastern Cooperative Oncology Group Performance Status(participants) | Pemetrexed + Carboplatin |
|---|---|
| 1 - Ambulatory, Restricted Strenuous Activity | 4 |
| Race/Ethnicity(participants) | Pemetrexed + Carboplatin |
|---|---|
| Caucasian | 4 |
The record gives a start of Sep 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Carboplatin